News | April 29, 2025
Pfizer Q1 2025 revenue drops 8% to $13.7 billion
Delivers robust earnings performance, successfully navigating a dynamic environment
Delivers robust earnings performance, successfully navigating a dynamic environment
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Bayer expects 2025 to be the most difficult year of its turnaround
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
The merged entity ‘Aster DM Quality Care’ will be jointly controlled by Aster Promoters and Blackstone
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
Subscribe To Our Newsletter & Stay Updated
